These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12899642)

  • 41. Viral delivery for gene therapy against cell movement in cancer.
    Wu TL; Zhou D
    Adv Drug Deliv Rev; 2011 Jul; 63(8):671-7. PubMed ID: 21616108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
    Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
    J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect.
    Harrison D; Sauthoff H; Heitner S; Jagirdar J; Rom WN; Hay JG
    Hum Gene Ther; 2001 Jul; 12(10):1323-32. PubMed ID: 11440625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system.
    Fink DJ; Ramakrishnan R; Marconi P; Goins WF; Holland TC; Glorioso JC
    Clin Neurosci; 1995-1996; 3(5):284-91. PubMed ID: 8914795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selectively replicating viral vectors.
    Nemunaitis J; Edelman J
    Cancer Gene Ther; 2002 Dec; 9(12):987-1000. PubMed ID: 12522438
    [No Abstract]   [Full Text] [Related]  

  • 46. Viral oncolysis.
    Donahue JM; Mullen JT; Tanabe KK
    Surg Oncol Clin N Am; 2002 Jul; 11(3):661-80. PubMed ID: 12487061
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
    Bauerschmitz GJ; Barker SD; Hemminki A
    Int J Oncol; 2002 Dec; 21(6):1161-74. PubMed ID: 12429964
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tissue-specific promoters for cancer gene therapy.
    Saukkonen K; Hemminki A
    Expert Opin Biol Ther; 2004 May; 4(5):683-96. PubMed ID: 15155160
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gene therapy applications of viral vectors.
    Lundstrom K
    Technol Cancer Res Treat; 2004 Oct; 3(5):467-77. PubMed ID: 15453812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Gene therapy: new developments].
    Mohr L; Geissler M
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2227-35. PubMed ID: 12564039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development.
    Moss B
    Dev Biol Stand; 1994; 82():55-63. PubMed ID: 7958483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Viral vectors for gene therapy.
    Robbins PD; Ghivizzani SC
    Pharmacol Ther; 1998 Oct; 80(1):35-47. PubMed ID: 9804053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer.
    Lucas T; Benihoud K; Vigant F; Schmidt CQ; Wortmann A; Bachem MG; Simmet T; Kochanek S
    PLoS One; 2015; 10(2):e0117254. PubMed ID: 25692292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Replication-competent herpes simplex vectors: design and applications.
    Argnani R; Lufino M; Manservigi M; Manservigi R
    Gene Ther; 2005 Oct; 12 Suppl 1():S170-7. PubMed ID: 16231051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy.
    Lambright ES; Amin K; Wiewrodt R; Force SD; Lanuti M; Propert KJ; Litzky L; Kaiser LR; Albelda SM
    Gene Ther; 2001 Jun; 8(12):946-53. PubMed ID: 11426335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial.
    Eck SL; Alavi JB; Alavi A; Davis A; Hackney D; Judy K; Mollman J; Phillips PC; Wheeldon EB; Wilson JM
    Hum Gene Ther; 1996 Aug; 7(12):1465-82. PubMed ID: 8844206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Oncolytic viruses for genetic therapy of gastrointestinal tumors].
    Bitzer M; Lauer UM
    Z Gastroenterol; 2003 Jul; 41(7):667-74. PubMed ID: 12858239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Replication-defective genomic HSV gene therapy vectors: design, production and CNS applications.
    Burton EA; Fink DJ; Glorioso JC
    Curr Opin Mol Ther; 2005 Aug; 7(4):326-36. PubMed ID: 16121698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.
    Wildner O; Morris JC
    J Gene Med; 2000; 2(5):353-60. PubMed ID: 11045429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.